Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 1, 2025
Distillery Therapeutics

Cas13 RNA editing of C9ORF72 repeat expansion for ALS and FTD

BioCentury | Oct 10, 2024
Guest Commentary

We cannot continue to ignore heterogeneity in ALS

The tools exist, it’s time to embrace them. Long-read sequencing is just one of the force-multipliers at hand
BioCentury | May 24, 2023
Finance

May 23 Quick Takes: VCs back cancer play Larkspur with $35.5M

Plus: PTC reports vatiquinone Phase III miss, discontinuation of gene therapies and updates from Innoviva, Pfizer, Wave, Arrowhead, Icosavax and more
BioCentury | May 28, 2022
Discovery & Translation

A synthetic lethal pair; plus Arbor and more

BioCentury’s roundup of translational news
BioCentury | May 20, 2022
Discovery & Translation

Precision’s chronic HBV gene therapy; plus Blaze and ASGCT highlights

BioCentury’s roundup of translational news
BioCentury | Apr 6, 2022
Data Byte

Wave next up in the C9orf72 pipeline

Four other therapies in preclinical development for ALS or FTD
BioCentury | Mar 29, 2022
Regulation

March 28 Quick Takes: Japan approvals include Sanofi’s Xenpozyme for rare disease

Plus more bad news for ALS and Biogen, Eagle acquiring Acacia, and more
BioCentury | Mar 9, 2022
Discovery & Translation

Wave takes its next-gen oligos beyond gene silencing and splicing

Preclinical data suggest the oligos can be used for base editing and modulating protein-protein interactions
BioCentury | Jan 27, 2022
Data Byte

Alzheimer’s foundation award roundup

Funding for Wave’s stereopure ASO, Optina’s awAIr cerebral amyloid status test
BioCentury | Oct 29, 2021
Discovery & Translation

Omics-based target identification in UK Biobank and COVID-19 cohorts 

Plus: technologies from Harvard, Texas A&M, Disney lab and more
Items per page:
1 - 10 of 57